GeneDx Holdings (WGS) Operating Expenses (2020 - 2026)

GeneDx Holdings (WGS) has reported Operating Expenses for 7 consecutive years, with $94.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Expenses rose 49.77% year-over-year to $94.4 million; the TTM figure through Mar 2026 stood at $272.5 million (up 48.4% YoY), while the FY2025 annual figure was $222.8 million, up 48.33% from the prior year.
• Operating Expenses rose to $94.4 million in Q1 2026 per WGS's latest filing, from $71.4 million in the prior quarter.
• Across five years, Operating Expenses topped out at $98.5 million in Q2 2022 and bottomed at $36.9 million in Q2 2024.
• Historically, Operating Expenses has averaged $60.5 million across 5 years, with a median of $57.1 million in 2023.
• Annual changes were most pronounced in 2022 — Operating Expenses soared 213.23% — and 2023, when it slumped 54.78%.
• GeneDx Holdings' Operating Expenses stood at $72.4 million in 2022, then tumbled by 34.5% to $47.5 million in 2023, then retreated by 16.29% to $39.7 million in 2024, then surged by 79.67% to $71.4 million in 2025, then jumped by 32.26% to $94.4 million in 2026.
• Business Quant data shows WGS's Operating Expenses at $94.4 million in Q1 2026, $71.4 million in Q4 2025, and $64.3 million in Q3 2025.